Karin Rosen
Directeur Technique/Scientifique/R&D chez HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Postes actifs de Karin Rosen
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Directeur Technique/Scientifique/R&D | 02/11/2020 | - |
| DIAMYD MEDICAL AB | Directeur/Membre du Conseil | 10/03/2023 | - |
Historique de carrière de Karin Rosen
Anciens postes connus de Karin Rosen
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GSK PLC | Corporate Officer/Principal | 01/11/2018 | 01/11/2020 |
Formation de Karin Rosen
| University of Lund | Doctorate Degree |
Statistiques
Internationale
| Suède | 3 |
| Irlande | 2 |
| Royaume-Uni | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GSK PLC | Health Technology |
| DIAMYD MEDICAL AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Bourse
- Insiders
- Karin Rosen
- Expérience
